创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

刘萧悦, 余子恒, 王信人, 唐伟方, 陆涛. 细胞周期蛋白依赖性激酶12抑制剂研究进展[J]. 药学进展, 2022, 46(3): 208-217.
引用本文: 刘萧悦, 余子恒, 王信人, 唐伟方, 陆涛. 细胞周期蛋白依赖性激酶12抑制剂研究进展[J]. 药学进展, 2022, 46(3): 208-217.
LIU Xiaoyue, YU Ziheng, WANG Xinren, TANG Weifang, LU Tao. Research Progress in Cyclin-dependent Kinase 12 Inhibitors[J]. Progress in Pharmaceutical Sciences, 2022, 46(3): 208-217.
Citation: LIU Xiaoyue, YU Ziheng, WANG Xinren, TANG Weifang, LU Tao. Research Progress in Cyclin-dependent Kinase 12 Inhibitors[J]. Progress in Pharmaceutical Sciences, 2022, 46(3): 208-217.

细胞周期蛋白依赖性激酶12抑制剂研究进展

Research Progress in Cyclin-dependent Kinase 12 Inhibitors

  • 摘要: 细胞周期蛋白依赖性激酶(CDK)在调节细胞周期和基因转录方面具有重要作用。其中CDK12主要负责调控基因转录过程,参与调节基因转录延伸、RNA剪接、转录终止以及DNA损伤修复等多个阶段。研究发现,CDK12的失调与多种肿瘤的发生发展有关。介绍CDK12的结构和生物学功能,以及其与肿瘤的关系,并对CDK12抑制剂的研究进展进行综述,旨在为CDK12调控机制的深入研究以及CDK12抑制剂的开发提供参考。

     

    Abstract: Cyclin-dependent kinase (CDK) plays an important role in cell cycle regulation and gene transcription. CDK12 can participate in gene transcription regulation by regulating gene transcription extension, RNA splicing, transcription termination and DNA damage repair (DDR). It is found that the dysregulation of CDK12 is related to the tumorigenesis and tumor metastasis. This article introduces the structure and biological functions of CDK12 as well as its relationship with tumors, and reviews the research progress in CDK12 inhibitors, aiming to provide reference for further research on the mechanism of CDK12 and the development in CDK12 inhibitors.

     

/

返回文章
返回